## - Amendments to the Specification -

Immediately after the title, please add the following cross reference:

## -- CROSS REFERENCE TO RELATED APPLCIATIONS

This application is a divisional application of copending United States Application Number 10/062,813, filed January 31, 2002, which claims the benefit of United States Provisional Application Number 60/265,492, filed January 31, 2001. --

After the last page of claims, please add the following Abstract of the Invention:

## -- ABSTRACT OF THE DISCLOSURE

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula:

where j is 0 or 1 provided that when j is 0, n must be 2; k is 0 or 1; m is 0, 1, or 2; n is 1 or 2; W<sup>1</sup> is -O—; or  $-S(=O)_t$ —, where t is 0, 1, or 2; or  $-N(R^3)$ —; W<sup>2</sup> is -O— $CR^AR^B$ — or is absent; Y is  $=C(R^1_a)$ — or  $-[N\Rightarrow(O)_k]$ — where k is 0 or 1; R<sup>A</sup> and R<sup>B</sup> are —H; -F;  $-CF_3$ ;  $-(C_1-C_4)$  alkyl; —  $(C_3-C_7)$  cycloalkyl; phenyl; or benzyl substituted with 0 to 3 substituents R<sup>10</sup>; or R<sup>A</sup> and R<sup>B</sup> are taken together, but only in the case where m is 1, to form a spiro moiety; R<sup>C</sup> and R<sup>D</sup> have the same meaning as R<sup>A</sup> and R<sup>B</sup> except that one of them must be -H, R<sup>1</sup> and R<sup>2</sup> are —H; —F; —CI; —CN; —NO<sub>2</sub>; — $(C_1-C_4)$  alkyl; — $(C_2-C_4)$  alkynyl; fluorinated— $(C_1-C_3)$  alkyl; — $OR^{16}$ ; and  $-C(=O)NR^{22}_aR^{22}_b$ ; R<sup>3</sup> is —H; — $(C_1-C_3)$  alkyl; phenyl; benzyl; or  $-OR^{16}$ ; R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> in addition to other meanings may be taken together to form, e.g.,

Q is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic, or that is a 7- to 12-membered, fused polycyclic; provided that Q is not a discontinuous or restricted biaryl moiety as defined under Q²; where optionally one carbon atom may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; Q² is a discontinuous or restricted biaryl moiety consisting of a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic, or that is a 7- to 12-membered, fused polycyclic; where optionally one carbon atom may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; Z is selected from: